A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis
Summary
- Eligibility
- for people ages 10-18 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Hoffmann-La Roche
- ID
- NCT04075266
- Phase
- Phase 2 research study
- Study Type
- Interventional
- Participants
- Expecting 36 study participants
- Last Updated